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1. Introduction  
Allogeneic stem cell transplantations (allo-SCT) increase in recipients the risk of life-
threatening opportunistic infections caused by different pathogens. In recent years, 
adenoviruses (AdV) have been recognized as an emerging pathogen causing serious post-
transplant complications with very high mortality (Fowler et al., 2010). Hematopoietic stem 
cell transplantation is a standard treatment in malignant and non-malignant disorders of 
bone marrow, solid tumors, immunodeficiencies, and autoimmune disorders (Gyurkocza et 
al., 2010; Ljungman et al., 2010). Intensive immunosuppressive treatment for prevention 
both of graft rejection and graft-versus-host disease (GvHD) and the therapy of the latter 
one, makes the patients at risk of developing opportunistic infections. The immune 
reconstitution period following hematopoietic transplantation is therefore accompanied by 
high incidence of adenoviral infections due to profound immunodeficiency (Echavarri´a, 
2008; Gyurkocza et al., 2010). Lack of immunological competence caused by invasive cancer 
therapy and conditioning procedures results mainly in lowering the number of CD3+ 
lymphocytes in peripheral blood. Lymphopenia increases patient`s risk for de novo 
infection or reactivation of a latent virus that mainly occurs during the early post-
transplantation period and usually leads to disseminated disease. The time of the infection 
onset is also vital, because AdV infections occurring after day +100 from the transplantation 
do not seem to be associated with life-threatening disease (Lion et al., 2003). According to 
different retrospective and prospective studies, adenovirus has been found to infect from 
just a few percent to a several dozen percent of patient post-HSCT (Akiyama  et al., 2001; 
Arnberg et al., 2002; Benko et al., 2000; Ebner et al., 2005; Howard et al., 1999; Mahr & 
Gooding, 1999; Lauer et al., 2003; Robin et al., 2007; Rutala et al., 2006; Stone et al., 2003; 
Walls  et al., 2003; Watzinger et al., 2004) with mortality in disseminated disease reaching 
even 80% (Akiyama et al., 2001; Mori  et al., 2003; Russell, 2000; Walls et al., 2003; Watzinger 
et al., 2004). Adenoviruses are commonly detected in stool, pharyngeal swabs, urine and 
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whole blood in HSCT recipients usually causing limited infections of the respiratory tract, 
gastrointestinal system and urinary tract but sometimes progress to disseminated disease 
affecting many organs and whole systems, too (Watcharananan et al., 2010). The diagnosis 
of adenoviral infection can be difficult due to complexity of the multiorgan disease non-
specific symptoms resembling other infections or acute graft versus host disease (aGvHD). 
This review describes adenoviral infections in recipients of hematopoietic stem cell 
transplantations and focuses attention on infection course, risk factors, possible 
complications, diagnostic methods for adenovirus identification and therapy strategies. 
2. Human adenoviruses-general description 
The original virus was isolated in 1953 from surgically removed adenoids from a child by 
Rowe et al. (Huebner et al., 1954; Rowe et al., 1953), thus it has been called adenovirus. 
Adenoviruses are ubiquitous in the environment contaminated with human feces or sewage. 
To date, 54 antigenic types of human adenoviruses belonging to genus Mastadenovirus and 
family Adenoviridae have been described, and over half of them have been recognized as 
pathogenic for humans. They have been divided into seven species (from A to G) on the 
basis of their morphological, hemagglutinating and oncogeneic properties as well as their 
genome size, DNA sequence and electrophoretic mobility of virion polypeptides (Table 1). 
Adenoviruses from species B and D were further subdivided into subspecies: B1, B2 and D1, 
D2 and D3, respectively. In addition to this classification several AdV genotypes can be 
identified within previously mentioned serotypes (Echavarri´a, 2008, 2009; Ebner et al. 2005; 
Stone et al., 2003; Wadell et al., 1980). 
Adenoviruses are non-enveloped, 70-90 nm in diameter particles with icosahedral 
symmetry. The capsid is composed of 252 capsomers: 240 hexamers and 12 pentons (Russell, 
2009; Rux et al., 2003). Several different proteins in AdV particle can be distinguished, but 
three major proteins such as hexon, penton base and fiber protein create the main capsid 
structure. The hexon is a homotrimer of three identical polypeptide chains (pII) formulating 
a triangular vertex of surface loops. It is the most abundant protein in adenoviral particle 
(more than 80% of AdV2 capsid protein) formulating hexon molecules symmetrically 
distributed in the capsid (Burnett, 1999). The hexon possess the group− and type−specific 
determinants which are utilized in diagnostic procedures such as ELISA test, 
hemagglutination inhibition and serum neutralization. Occurrence of these specific antigen 
determinants on a viral surface is determined by the presence of variable and hypervariable 
regions (HVRs) in nucleotide sequence of the hexon gene. Since today, nine hipervariable 
regions (HVR1-HVR9) have been distinguished (Crawford-Miksza & Schnurr, 1996; Rux et 
al., 2003). They are situated within the loops at the top of the hexon molecule, hence can be 
utilized in diagnostic tests. The hexon protein is also an immunodominant T-cell target, 
however other structural components of the virion may also be immunogenic. Twelve 
penton bases (pIII) creating capsid vertex provide the basis for radially projecting trimeric 
fibers (pIV) of different lengths according to the AdV serotype (10-37 nm). The external end 
of the fiber is terminated with a C-terminal knob which posses several antigen determinants 
participating in cell receptors binding, hemagglutination in vitro and virus internalization 
into a host cell (Burmeister et al., 2004; Cusack, 2005; Echavarri´a, 2008). Genetic information 
of adenoviruses is encoded by about 34-36 kb double stranded linear DNA, containing more 
than 50 coding regions (Echavarri´a, 2008). 
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Species Serotypes Features#  
A 12, 18, 31 Highly oncogenic 
GC%: 47-49 
FL: 28-31nm 
HA: rat (incomplete) 
 
B B1: 3, 7, 16, 21, 50† 
B2: 11, 14, 34, 35 
Poorly oncogenic 
GC%: 48-52 
FL: 9-11 nm 
HA: Rhesus 
 
C 1, 2, 5, 6 Nononcogenic 
GC%: 55-59 
FL: 23-31nm 
HA: rat (incomplete) 
 
D D1: 9, 19 
D2: 15, 22 
D3: 8, 10, 13, 17, 20, 23-30, 32, 
33, 36-39, 42-49, 51†, 53, 54* 
Nononcogenic 
GC%: 54-59 
FL: 12-13 nm 
HA: rat, mouse, human, dog, pig, monkey 
 
E 4 Nononcogenic 
GC%: 57 
FL: 17 nm 
HA: Rat (incomplete) 
 
F 40, 41 Nononcogenic 
GC%: 51-59 
FL: 29 nm 
HA: rat (atypic) 
 
G 52 ND  
# Data adopted from references: (Echavarria, 2006; Hierholzer, 1992; Kaneko et al., 2009; Wadell  et al., 
1980; Walsh et al., 2010; and from National Center for Biotechnology Information database 
(http://www.ncbi.nlm.nih.gov); 
† according to  Ebner et al. (2005) serotype 50 was reclassified into species D and serotype 51 into 
species B; 
* firstly described in year 2009, (proposal) (Kaneko et al., 2006); 
ND- not determined, FL-fiber length, HA- hemaglutination; 
Table 1. Adenovirus classification and general features. 
3. Virus transmission in stem cell recipients 
The most common source of adenoviral infection after haematopoietic stem cell 
transplantation is reactivation of a latent virus persisting in lymphocytes of peripheral 
blood, in adenoids, intestines and kidneys through low-grade replication. AdV1, AdV2 and 
AdV5 (C) are the most common serotypes remaining latent after primary exposure in the 
childhood (Lee et al., 2010; Malekshahi et al., 2010). They also play the significant role in 
development of AdV infections after SCT, therefore confirming the role of virus reactivation 
during an early post-transplant period. The next source of AdV infection in stem cell 
recipients might be the virus transmission from the positive donor to the negative recipient. 
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There are many reports confirming more than 4-fold increased risk of primary adenoviral 
infections in HSCT recipients grafted from previously infected (seropositive) donors in 
comparison to uninfected donors (Runde et al., 2001; Walls et al., 2003). 
Adenoviruses can spread directly through respiratory droplets hence upper respiratory tract 
infections occur very often. They are able to replicate in the environment of the 
gastrointestinal tract due to their resistance to low pH of a stomach and proteolytic enzymes 
in gastrointestinal secretions, thus allowing the virus to achieve a high viral load in the gut. 
Because viral loads in stool samples of infected patients achieve the highest levels in 
comparison to other clinical materials, it can be suggested that fecal-oral transmission is the 
most common route of infection spread (Baldwin et al., 2000; Chakrabarti et al., 2002; Hale et 
al., 1999; Howard et al., 1999; Jeulin et al., 2011; Lion et al., 2010; Rutala et al, 2006).  
There are also some reports suggesting possible virus spread via unsterile instruments and 
medical equipment, direct staff-to-patient transmission or inadequate air conditioning in the 
post-transplantation ward. Adenoviruses are strongly resistant to chemical or physical 
agents and adverse pH conditions and are able to remain infectious for a long period 
outside of the body, but this route of infection can be prevented by disinfection procedures 
in transplantation units (Artieda et al., 2010; Gerber et al., 2001; Gray, 2006; Leruez-Ville et 
al., 2006; Lessa et al., 2007; Romero et al., 2010). 
4. Pathomechanism and clinical manifestations of adenoviral infections  
Individual serotypes of Adenoviridae family show varied tissue tropism. They infect post-
mitotic cells of even highly differentiated tissues such as skeletal muscles, lungs, brain and 
heart muscle (Russell, 2009; Zhang & Bergelson, 2005). The infection cycle is divided into 
two stages involving virus adsorption and internalization (Figure 1). Attachment to the host 
cell receptor and virus entry occurs via the fibre protein and penton base. Majority of 
adenoviruses (mainly those from species A, C, D, E and F) use the coxackie-adenovirus 
receptor (CAR) which is a member of the immunoglobulin family and is situated on a 
surface of most human tissues such as heart muscle, brain, liver, pancreas, intestines, lungs 
and kidneys (Dechecchi et al, 2001; Raschperger et al., 2006; Russell, 2000, 2009; Rux et al., 
2003; Zhang & Bergelson, 2005). In human cells lacking CAR receptor, other cell molecules 
are used for virus attachment. For example, AdV2 and AdV5 are able to bind the ǂ-domain 
of MHC class I (Major Histocompatibility Complex Class I) molecule or heparan sulfate 
glycosaminoglycans (HS GAG). Additionally, these serotypes are capable to recognize and 
interact with vascular cell adhesion molecule-1 (VCAM-1) which is situated on 
atherosclerotic lesions of vascular endothelium. More rarely, ǂ(2-3)- sialic acid, sBAR and 
sB2AR and CD46, CD80, CD86 are used (mainly serotypes: 3, 7, 8, 11, 14, 16, 19, 21, 37, 34 , 
35 and 50) (Benko  et al., 2000; Burmeister  et al., 2004; Chu  et al., 2001; Sharma et al., 2009; 
Wang et al, 2007; Zhang & Bergelson, 2005). Virus binding to the cell receptor and 
interaction between penton base and integrins on the target cell induce internalization of the 
viral particle into the host cell by clathrin-coated vesicles and endosomes. Several proteins 
and intra-endosomal mechanisms lead to disintegration of virus particle and subsequently 
to viral core release. Viral DNA is transported to the cell nucleus by microtubule-mediated 
transport and undergoes DNA transcription and replication (Cusack, 2005; Kelkar et al., 
2004; Russell, 2000). Replication process is divided into an early and late phase. Sometimes, 
an intermediate phase is also marked out. The early phase (6-8 hours) includes virus 
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penetration into the host cell, transport of viral DNA to cell nucleus and 
transcription/translation of the “early genes” such as E1A, E1B, E2, E3, E4. The products of 
the early genes act as regulatory factors. They change cell functions to facilitate further 
replication of the virus and transactivate other early transcription units. Second phase of 
AdV replication leads to transcription and translation of the “late genes” (L1-L5) encoding 
mainly structural proteins of the virion shell. Assembly and maturation of AdV particles 
take place in the nuclei of infected cells. The whole process usually takes only 4-6 hours 
(Greber et al. 1997, Gonçalves & de Vries, 2006; Matthews & Russell, 1998; Russell, 2000). 
 
 
Fig. 1. AdV infection cycle. An interaction between penton base and ǂ,ǃ integrins induces 
internalization of viral particle into the host cell. Intra-endosomal mechanisms lead to 
disintegration of virion shell. Viral DNA is transported into the cell nucleus providing 
material for DNA replication. The early phase of replication includes expression of the 
“early genes” (E1-E4) acting as regulatory factors and facilitating virus replication. Second 
phase of AdV replication leads to expression of L1-L4 encoding mainly structural proteins 
determining virus assembly and maturation. 
Adenoviral infection and active virus replication in the host cell can exert three different 
cytopathological effects. In most cases AdV infection leads to cell lysis. AdV genome 
contains at least four different coding regions (E1a, E4ORF4, E4ORF6/7 i ADP, which 
products can induce cell death and lysis (Braithwaite & Russell, 2001). Alternatively, after 
acute phase of the infection, the virus might remain in latent phase. Human adenoviruses, 
especially AdV1, AdV2, AdV5 from species C, possess the ability to prolonged persistence 
in adenoids, intestines, renal parenchyma and lymphocytes in peripheral blood with 
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periodic shedding of virus in feaces and respiratory secretions (Akiyama et al., 2001; 
Braithwaite & Russell, 2001; Echavarri´a, 2008; Watzinger et al., 2004). The third possible 
outcome of adenoviral infection is an oncogenic transformation of infected cells, that is 
observed in animal models (Russell, 2009). 
Primary adenoviral infections affect predominantly pediatric population with more than 
50% of children infected before the age of five (Cooper et al., 2003). Children are often 
infected with adenovirus types 1, 2, 3, 4, 5, 7 and 30 which are the most common causes of 
tonsillopharyngitis and pneumonia (Carballal et al., 2002; Faden et al., 2005). These antigenic 
types are also the most frequent in recipients of SCT indicating virus reactivation or droplets 
transmission as most reliable routes of virus spread. AdV infections in immunocompetent 
humans are usually asymptomatic, localized and tend to be self-limited. They are restricted 
to the respiratory system, genitourinary and gastrointestinal tract infections, occasionally 
affecting conjunctiva and cornea. Recipients of HSCT and other imunocompromised 
patients present much broader spectrum of clinical manifestations. According to different 
studies, the estimated rate of AdV infection after HSCT ranges from 3–47% (Akiyama  et al., 
2001; Arnberg  et al., 2002; Ebner  et al., 2005; Howard et al, 1999; Lauer et al., 2004; Mahr & 
Gooding, 1999; Rutala et al., 2006; Stone et al., 2003; Walls et al, 2003; Watcharananan et al, 
2010; Watzinger et al., 2004;) with mortality reaching up to 80% in patients with 
disseminated disease (Akiyama  et al., 2001; Kaneko  et al., 2009; Russell, 2000; Walls et al., 
2003; Watzinger  et al., 2004). The wide range in reported AdV incidence can results from 
different diagnostic methods, variety of body sites analyzed as well as demographic 
differences and lack of strict criteria for defining adenovirus infection or disease. AdV 
infections in immunocompromised patients tend to be invasive. The most common are 
infections of AdVs from subgroup C, followed by A, B and D. They cause exudative 
pharyngitis, acute respiratory disease epidemics, febrile laryngitis, conjunctivitis, 
keratoconjunctivitis, necrotizing enterocolitis, pharyngeal−conjunctival fever and 
hemorrhagic cystitis. Less frequent are testitis, nephritis, arthritis, myocarditis and 
pericarditis. Infections of the gastrointestinal tract are especially frequent in young children 
and include gastroenteritis, mesenteric lymphadenitis, intussusception, hepatitis, and 
appendicitis (Table 2) (Akiyama et al., 2001; Arnberg  et al., 2002; Benko, 2000; Chakrabarti 
et al., 2000; Chmielewicz  et al., 2005; Ebner  et al., 2005; Echavarria, 2009;  Ephros et al., 
2009; Howard  et al., 1999; Ison, 2006; Jones  et al., 2007; Kaneko  et al., 2009; Lim et al., 2005; 
Mori et al., 2003; Robin et al., 2007; Runde et al., 2001; Venard et al., 2000;  Walsh  et al, 2009). 
Most adenoviral infections in patients following HSCT occur during an early post-
transplantation period, within 2-3 months (Ephros et al., 2009; Lion et al., 2010; 
Watcharananan et al., 2010). Adenovirus infections in patients after stem cell 
transplantations can occur throughout the year but there are some reports suggesting 
seasonal fluctuations of adenoviral infections indicating greater incidence in autumn and 
winter, 52-70% (Bil-Lula et al., 2010). 
An intensity of virus replication depends on a site of infection. The highest viral loads are 
observed in gastrointestinal tract infections (even more than 108 copies/g of stool) and in 
upper respiratory tract infections (104 -106 copies/ml). Whole blood viraemia remains at a 
moderate level and usually does not exceed 103 – 104 copies per ml, whereas in plasma 
samples only trace amounts of AdV particles can be detected (< 102 copies/ml). Some of 
patients with moderate viraemia are able to self-eliminate of the virus within 2-4 weeks. 
However most patients presenting disseminated infections (> 107 copies/ml) die due to 
www.intechopen.com
 
Adenoviral Infection – Common Complication Following Hematopoietic Stem Cell Transplantation 
 
539 
adenoviral infection within short time (Ephros et al., 2009; Heim et al., 2003; Lion et al., 2003; 
Walls et al., 2005). 
 
Clinical symptoms Involved serotypes 
Acute follicular conjunctivitis and keratoconjunctivitis 1, 3, 4, 5, 7, 8, 9, 11, 16, 19, 26, 27, 
30, 37, 53, 54 
Acute hemorrhagic cystitis (HC) 3, 7, 11, 21, 34, 35 
Acute respiratory disease 1, 2, 3, 4, 5, 6, 7, 14, 21, 30 
Exudative pharyngitis 1, 2, 3, 5, 7 
Gastroenteritis 1, 2, 12, 16, 18, 31, 40, 41, 52 
Hepatitis, appendicitis 1, 2, 3, 5, 7 
Intussusception 1, 2, 5 
Meningitis, encephalitis 2, 3, 7, 12, 32 
Myocarditis 7, 21 
Nephritis and kidney damage 11, 14, 34, 35 
Pertussis−like syndrome 5 
Pharyngitis 1, 2, 3, 5, 7 
Pharyngoconjunctival fever (PCF) 3, 4, 7, 14 
Pneumonia 1, 2, 3, 4, 7, 11, 14, 21, 30, 34, 35 
Prolonged diarrhea 40, 41, 52 
Ulcerative changes in the female genital organs, cervicitis 19, 37 
Urethritis 1, 3, 4, 7, 14, 16, 19, 34, 35, 37, 50 
Table 2. Clinical manifestations of adenoviral infection in stem cell transplant recipients 
(summary table). 
5. Anti-viral response and viral immunoavoidance 
Virus penetration into human organism induces both specific and non-specific response to 
infection. Firstly, virus by binding with the cell receptors activates congenital mechanisms of 
anti-viral defense. An induction of the inflammatory response stimulates interferon 
production by both immunocompetent and non-immunocompetent cells. Macrophages, 
natural killers (NK cells) and complement proteins are also involved in anti-adenovirus 
defense indirectly by killing infected cells or due to production of cytokins such as Il-1, Il-6 
and TNF-ǂ. Additionally, Smith et al. (2008) confirmed the role of the epithelial defensins 
which coat the capsid vertex of adenoviral particle and inhibit virus uncoating in cytoplasm 
of infected cell (Smith & Nemerow, 2008). Another way of virus elimination from the 
organism is induction of pro-apoptotic mechanisms in infected cells due to e.g. p53, TNFǂ 
and Bax proteins (Randall & Goodbourn, 2008; Russell, 2000, 2009; Smith & Nemerow, 
2008). Very important role in viral clearance is played by acquired immunity mechanisms. 
The cellular response is limited to CD3+ cells activation (both helper and cytotoxic 
lymphocytes) which also produce TNFǂ and INFɣ. Activation of CD8+ cells due to 
presentation of hexon determinants in MHC I complex leads to eradication of infected cells 
by means of cell perforation and lyses. This mechanism prevents virus replication and 
further spread of viral particles. The humoral response is focused on production of 
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neutralizing antibodies. The neutralizing antibodies recognize HVRs and the fiber 
determinants leading to agglutination of virus particles and interrupting infection of new 
cells. The presence of anti-adenoviral antibodies in patient serum grants permanent 
immunity against AdV (Baldwin et al., 2000; Crawford-Miksza & Schnurr, 1994; Leen et al, 
2008; Russel, 2009; Rux et al., 2003; Schilham et al., 2002; Walls et al., 2003). 
Intensity and length of immunosuppressive therapy are tailored to the risk of graft-rejection 
or graft versus host disease.  
The prevention and therapy of GvHD is crucial in allogeneic HSCT recipients, which 
explains its intensity and diversity by combining drugs (cyclosporine, tacrolimus, 
mycophenolate mofetil) with biological agents (OKT-3, alemtuzumab, ATG) or graft 
engineering methods like T-cell depletion/CD34+ positive selection. Immunosupression 
determinates  stable engraftment and prevents from GvHD, but increases risk of disease 
relapse or opportunistic infections, due to depletion of donor lymphocytes necessary for 
graft-versus-tumor (GVT) effects and delayed immune reconstitution (Gyurkocza et al., 
2010). 
Immune defense against adenoviral infections is hampered by viral abilities for avoidance of 
both humoral and cellular host immune response. By means of E1A (early region 1A) and 
VARNAs (virally associated RNAs) they developed the ability to inhibit human interferons 
ǂ and ǃ. The product of E1B inhibits apoptosis of infected cells.  Moreover, product of E3 
coding region can inhibit a transport of MHC I particles to the cell membrane disturbing 
viral antigens presentation to the cytotoxic lymphocytes (CLS) (Braithwaite & Russell, 2001; 
Lauer et al., 2004; Mahr & Gooding, 1999; Russell, 2000; Stone et al., 2003). Some of E3 
products interfere with pro-inflammatory and cytolytic activity of TNF or remove Fas and 
TRAIL receptors from cell surface (Echavarria, 2009). The fact, that these proteins are 
expressed during early stage of transcription, protects infected cells from immune 
surveillance. 
6. Risk factors for development of adenoviral infection after HSCT 
The hematopoietic stem cell transplantation recipients constitute a group of patients with an 
extremely high risk of death due to opportunistic infections, and among them the AdVs are 
accounted to most challenging pathogens responsible for fatal outcome. The problem of 
AdV infections after HSCT is a consequence of different factors affecting recipient`s 
immunity. Development of graft versus host disease and its prophylaxis or therapy with 
potent immunosuppressants  are the reasons  for  numerous opportunistic infections.  The 
anti-leukemic efficacy and early complications of HSCT result from both intensity of the 
conditioning regimen and the graft-versus-leukaemia (GVL) effect. However, conditioning 
strategies with high doses of cytotoxic and immunosupressive drugs lead to tissue damage, 
cytokine storm and profound impairment of patients immunity, thus increasing patient`s 
risk of de novo infection or reactivation of latent adenovirus during a post-transplantation 
period. Reduced-intensity conditioning (RIC) regimens lower the risk for AdV infection due 
decreased organ damage and lower proinflammatory cytokines secretion, hence protecting 
the patient from aGvHD but maintaining an effect of GVL (Couriel et al., 2004; Gyurkocza et 
al., 2010; Hill& Ferrara, 2000; Pérez-Simón et al., 2002, 2005). The clinical course of AdV 
infection after HSCT is different from the one observed in immunocompetent individuals. 
AdVs usually cause permanent and stubborn infections in those patients because 
immunological response to adenoviruses following SCT is very poor. In rare situations, AdV 
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can be responsible for graft rejection or delayed implantation of stem cells (Hierholzer, 1992; 
Ison, 2006).   
Risk factors affecting patient`s susceptibility to adenovirus infections after stem cells 
transplantation are well known (Figure 2). Many reports indicate increased morbidity 
among recipients of allogeneic grafts from matched unrelated donors (MUD) in comparison 
to partially matched family donors (PMFD) (Baldwin et al. 2000; Bruno et al., 2003; Ebner et 
al., 2005; Gu et al., 2003; Hale et al., 1999; Howard et al., 1999; Ison, 2006; Legrand et al., 
2001; Lion et al., 2003). An incidence of AdV infections and patient`s mortality due to 
infection in this group reach about 5-47% and 60%, respectively (Hierholzer, 1992; Howard 
et al., 1999; Leruez-Ville et al., 2006; Lim et al., 2005; Robin et al., 2007; Runde et al., 2001; 
Venard et al., 2000; Walls et al., 2005). In recipients of autologous transplantations AdV 
infections prevalence is much lower, about 1-14% (Baldwin et al., 2000; Bruno et al., 2003; 
Hale et al., 1999; Howard et al., 1999; Teramura et al., 2004). Significant differences in 
occurrence of adenoviral infections are believed to result from more aggressive and longer 
immunosuppressive therapy after allogeneic transplantations (Walls et al., 2003). Lack of 
endogenous T-cell immunity makes patient more predisposing to development of 
adenoviral infection and disseminated disease with fatal outcome (Bil-Lula et al., 2010; 
Feuchtinger et al., 2008; Watcharananan et al., 2010). Therefore, delayed immune recovery 
after stem cell transplantation has critical impact on progression of adenoviral infections. 
Moreover, second allotransplantation also increases patient`s susceptibility to AdV infection 
(Bruno et al., 2003).  
Another risk factor for development of adenoviral infections in HSCT recipients is patient`s 
age. There are many reports confirming that children and adolescents are at greater risk of 
adenovirus infection than adults (Robin et al., 2007; Walls et al., 2005). Greater susceptibility 
of younger patients may results from immaturity and worse efficiency of immune system in 
comparison to older recipients. Moreover, persistent infections are predominantly caused by 
AdV from species C, which are common etiological factor of adenoviral infections in a 
childhood. Combination of immunosupression and young age of graft recipients can lead to 
intensified replication of adenoviruses and to greater viral load in clinical samples (more 
than 105 copies /ml) in comparison to adult recipient (viral load usually not exceeds 103 
copies /ml) (Baldwin et al., 2000; Bruno et al., 2003; Chakrabarti et al., 2002; Howard et al., 
1999; Heim et al., 2003; Ison, 2006; Robin et al., 2007; Walls et al., 2003). 
The role of T-cells in controlling the AdV infection is unquestionable. The graft engineering 
methods involving ex-vivo removal of T-cells by CD34+ positive selection or by lymphocyte 
depletion are very effective in respect of GvHD reduction but cause profound long-term T-
cell deficiency and function impairment. Adenoviral infections due to reactivation of latent 
virus are also reported more frequently (more than 70%) in recipients of manipulated grafts 
in comparison to those who received graft containing donor`s lymphocytes (25%). 
Moreover, some reports suggested delayed recovery and lower overall survival in patients 
undergoing T-cells depletion (Chakrabarti et al, 2002; Ison, 2006; Lion et al., 2003; Venard et 
al., 2000; Walls et al., 2003, 2005). 
The development and severity of graft versus host disease are typically identified 
independent risk factors for progression of adenoviral infection after stem cell 
transplantation. The mechanism of GvHD induction is multifactorial and despite intensive 
research only moderately understood, the incompatibilities in HLA and in minor 
histocompatibility antigens (mHA) are generally recognized causes for its occurrence 
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(Gyurkocza et al., 2010). It was reported that moderate to severe aGvHD and its therapy 
may facilitate virus replication in recipients of SCT (Baldwin et al., 2000; Bil-Lula et al, 2010; 
Bruno et al., 2003; Ison, 2006; Robin et al., 2007; Runde et al., 2001;  Watcharananan  et al., 
2010). GvHD requires immunosuppressive therapy which lowers the number of 
lymphocytes and hampers the immunity of the recipient, thus enabling adenoviral 
infections. A low lymphocyte count due to non-specific T-cell depletion or delayed T-cell 
reconstitution is considered as important predictor for detection of adenoviral infections. An 
inadequate humoral response due to B lymphocyte impairment contributes to greater 
susceptibility to AdV infection (Chakrabarti et al., 2000, 2002; Heemskerk et al., 2005). 
Some authors emphasize that presence of adenovirus in peripheral blood or plasma is an 
indicator of impending symptomatic adenoviral disease and multiorgan failure in patients 
undergoing HSCT. Chakrabarti et al. (2002) and others confirmed a strong correlation 
between the presence of adenovirus in whole blood/plasma and an increased mortality due 
to infection (9-86%) (Chakrabarti et al., 2002; Ebner et al., 2005; Echavarria  et al, 2001; Lion  
 
 
Fig. 2. Risk factors for adenoviral infections in patients after haematopoietic stem cell 
transplantation. 
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et al., 2003; Robin et al, 2007; Schilham et al., 2002; Watcharananan et al., 2010). High viral 
load in plasma samples (106-107 copies/ml) should be considered as a risk factor for serious 
post-transplantation complications (Ison, 2006; Claas et al., 2005), but the issue is still 
controversial because other authors did not confirm the relationship between viral load and 
severity of infection (Walls et al., 2005). In some studies were reported patients who despite 
high viral load in blood recovered from adenoviral infection without any treatment. It 
suggests that not each adenoviral infection needs antiviral treatment (Lankester et al., 2002; 
Schilham et al., 2002).  
It needs to be mentioned that the source of progenitor cells also plays a significant role in 
development of adenoviral infection. It was confirmed that transplantation of peripheral 
blood progenitor cells (PBPCs) increases an incidence of AdV infections in hematological 
patients in comparison to bone marrow transplantations (BMT) due to high number of 
lymphocytes transferred with the graft. Adenovirus latency in peripheral lymphocytes may 
be a source of infection in those patients (Runde et al., 2001). On the other hand, unrelated 
cord blood transplantations (UCB) are suggested to be an independent risk factor for AdV 
infections (Robin et al., 2007) due to lack of mature lymphocytes in CB regarded as the major 
component of antiviral defense. Therefore it is still controversial issue. 
7. Co-infections in patients undergoing stem cell transplantation 
Recipients of stem cell transplantations with AdV infection are prone to life-threatening 
multiple opportunistic infections. Simultaneous infections of adenoviruses and CMV (4,3- 
73%), EBV (2,8-34%),  polyoma BK (BKV) (1,7-20%),  HSV (6,7-26,6%) or RSV (3,8-13%) are 
most frequently reported (Baldwin et al., 2000; Bruno et al., 2003; Chakrabarti et al., 2002; 
Leruez-Ville et al., 2006; Lion et al., 2003; Myers et al., 2005; Watcharananan et al., 2010). Co-
infections of AdV and BKV are usually detected in urinary tract of immunocompromised 
patients leading to intensification of hemorrhagic cystitis sympthoms (Akiyama et al., 2001). 
It was also found that CMV viraemia leads to more than 4-fold increase in patient`s risk for 
development of AdV infection (Baldwin et al., 2000; Watcharananan et al., 2010). In rare 
cases, co-infections of AdV and other viruses such as: HSV1, RSV, EBV and rotaviruses were 
observed (Legrand et al., 2001; Robin et al., 2007). Many reports suggested that infection of 
one AdV serotype increases patient`s risk for co-infection with second type of human 
adenovirus leading to extensive organ and whole system involvement (Echavarria et al., 
2006; Kroes et al., 2007; Watcharananan et al., 2010). 
8. Diagnostic methods for adenovirus detection and identification 
Permanently growing number of hematopoietic transplantations in recent years and high 
risk of viral complications following this procedure demands an implementation of better 
and more effective diagnostics methods for detection and monitoring of viral infections. 
There are several methods commonly used for adenovirus detection and identification in 
clinical samples. Serological tests, virus isolation in cell culture, microscopic techniques and 
molecular methods found their way into clinical practice.  
Virus isolation in cell culture is still considered a “gold standard” for detection of adenoviral 
infection. Different cell lines like A549, Graham 293 and HEp-2 can be used for virus 
isolation from clinical samples such as stool, throat swabs, conjunctival swabs, urine and 
biopsy specimens. Within several days of culturing, cythopatic effect as clumping and cell 
rounding can be observed (Figure 3). 
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Fig. 3. Microscope image of A549 cells. (A) native culture; (B) cythopatic effect occurring 
within 48 hours since AdV21 infection (species B). Own collection. 
This reference method provides virus identification and typing by means of serum 
neutralization (SN), hemagglutination inhibition (HI) and complement fixation tests. 
Unfortunately, the culture technique is laborious, time-consuming and lacks sensitivity to 
detect virus in the early phase of infection. It can also be inhibited by neutralizing antibodies 
or other interfering substances (Echavarria, 2009; Huang & Turchek, 2000; Raboni et al., 
2003). Nowadays, due to its disadvantages it is replaced by new, more reliable methods like 
molecular tests. 
The next conventional methods for detection of adenoviral infection are serological tests. 
They are used for indirect antigen detection on capsid surface (IFA, RIA) allowing for virus 
identification in highly concentrated samples of respiratory secretion, pharyngeal swabs and 
stool or to confirm AdV infection on the basis of specific antibodies detection. ELISA tests 
are also used for identification of AdV-antibodies in patient`s serum (Echavarria, 2009; 
Hierholzer et al., 1993; Madisch et al., 2005; Raboni et al., 2003). Although serological tests 
are commonly used in routine diagnostics of viral infections they are not recommended in 
adenoviral infections due to their insensitivity, low specificity, false negative results during 
the window period and difficulties arising from virus variability (Chirmule et al., 1999; 
Chmielewicz et al., 2005; Crawford-Miksza & Schnurr, 1994; Echavarria, 2009; Raboni et al., 
2003). Furthermore, serological tests are useless in recipients of SCT due to profound 
immunosuppression and using of anti-viral drugs.  
The characteristic icosahedral morphology of adenoviruses can be utilized in virus detection 
by use of electron microscopy (EM) and other microscopic techniques. Infected cell are 
characterized by presence of enlarged nuclei containing crystalline inclusions of adenoviral 
particles. Nonetheless, this method is limited by access to unique equipment and EM 
requires a large number of viral particles in clinical sample hence it can be mainly used in 
diagnostics of acute gastroenteritis and upper respiratory tract infections (Chirmule et al., 
1999; Roingeard, 2008). 
Numerous limitations of conventional methods make these techniques impractical in 
routine diagnostics. The culture collection, serological tests and microscopic techniques are 
laborious, time-consuming, and insensitive especially in an early phase of the infection. 
Hence in recent years, molecular methods dominate virus detection and identification in 
clinical practice. Identification of adenovirus by polymerase chain reaction (PCR) facilitates 
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accurate and rapid diagnostics and surveillance. PCR is currently the most widespread 
method used for detection of microbial infections. In comparison to conventional techniques 
it offers high sensitivity and specificity as well as possibility to obtain a reliable result within 
several hours. This method allows detecting even small number of viral particles in largely 
cell-free fluids such as plasma, serum, urine (centrifuged), cerebrospinal fluids and others, 
preferably before clinical manifestation and tissue damage (Ephros et al., 2009). It can also 
be implemented for detection of AdV serotypes which are potentially considered as not 
growing in routine cell culture. Moreover, polymerase chain reaction may be employed for 
detection of variance and mutations in virus genome (Powledge, 2004). In combination with 
other methods such as sequencing of hyper variation regions (HVRs) or restriction fragment 
length analysis, PCR may be used for AdV typing. During last years, the quantitative real-
time PCR (RQ-PCR) technique has been successfully implemented more often in viral 
diagnostics (Bil-Lula et al., 2010; Claas et al., 2005; Echavarria et al., 1999, 2001; Gu et al., 
2003; Heim et al., 2003; Hierholzer et al., 1993; Lankester et al., 2002; Lion et al., 2003; 
Watzinger et al., 2004). Use of highly specific probes allows sensitive detection and 
quantification of viral equivalents in clinical samples. Sensitive and reliable monitoring of 
viral replication in immunocompromised patient is extremely important due to possibility 
for dissemination of infection and poor outcome. It has also a prognostic significance for the 
patient. Moreover, monitoring of active replication and increasing viral load in clinical 
samples constitutes the basis for differentiation of active and latent infection in recipients of 
stem cell transplantations. On the other hand, an early detection of adenovirus due to highly 
sensitive RQ-PCR creates the opportunity for reduction of immunosuppressive therapy or 
early initiation of preemptive anti-viral agents before onset of fulminant disease, 
simultaneously determining therapy effectiveness (Mori et al., 2003). It was confirmed that 
weekly surveillance of samples for AdVs and early intervention with anti-AdV agents 
results in significant reduction in the disseminated disease rate and fatal outcomes 
(Sivaprakasam et al., 2007; Yusuf et al., 2006). 
9. Treatment strategies for adenoviral infections 
There are many reports describing treatment trials of adenoviral infections in recent years. 
However, treatment of AdV infections remains a serious problem due to lack of 
unequivocally proven effectiveness of used drugs. Therefore adenoviral infections in 
immunocompromised patients should be considered as a serious, life-threatening 
complication. 
Due to numerous toxicities and limitations, administration of anti-AdV drugs should be 
tailored to the patients situation and risk of dismal outcome.  In severe AdV infections 
usually cidofovir (CDV) or ganciclovir are administered (Bordigoni et al., 2001; Hoffman et 
al., 2001; Legrand et al., 2001). Other anti-viral drugs such as vidarabine and ribavirine may 
be implemented (Bordigoni et al., 2001; Miyamura et al., 2000). It was demonstrated that 
ribavirin (usually used in treatment of HCV and RSV infections) is highly effective in 
treatment of localized AdV infections in urinary tract but is of limited efficacy in 
disseminated infections (Bordigoni et al., 2001; Gavin & Katz, 2002; Hoffman  et al., 2000; 
Lankester et al., 2004). Some studies also confirmed partially the ability to virus elimination 
from urine samples after cidofovir administration in patients suffering from hemorrhagic 
cystitis. Unfortunately, CDV shows numerous side effects such as renal toxicity, 
carcinogenicity and toxic injury of muscles (Bordigoni et al., 2001; Feuchtinger et al., 2006, 
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2008). Despite all these side effects, lack of other more effective medicaments dictates the 
application of these drugs in therapy of adenoviral infections of urinary tract, 
gastroenterititis and pneumonia (Bruno et al., 2003; Ebner et al., 2006; Heim et al., 2003; 
Hoffman et al., 2001; Legrand et al., 2001, Uchio et al., 2007). New antiviral agents are under 
development. CMX001 is a new formulation of cidofovir. It is oral lipid conjugate of CDV, 
potentially highly effective against all dsDNA viruses, including adenoviruses (Fowler et al., 
2010; Randhawa et al., 2006). Novel form of cidofovir is characterized by convenient oral 
supply, decreased dose and lack of affinity to kidney tissue. Due to insufficient effectiveness 
of previously used drugs, new clinical trials are still carrying on. New candidates for 
treatment of adenoviral infections are also zalcitabine and stavudine, commonly used as 
anti-HIV agents (Inoue et al., 2009; Romanowski et al., 2009). Zalcitabine is a reverse 
transcriptase inhibitor which may be used in treatment of AdV infections caused by 
serotypes: 2, 3, 4, 8, 19 and 37. Unfortunately, only low dosed of zalcitabine may be 
administrated because of its mitochondrial toxicity and possibility of peripheral neuropathy 
and esophageal varices. Stavudine, in turn, is an analogue of pyrimidine nucleoside which 
inhibits the activity of reverse transcription. It may be potentially used in treatment of AdV3 
and AdV4 infections (Inoue et al., 2009; Romanowski et al., 2009; Uchio et al., 2007). 
Timing of therapeutical intervention plays important role, too. There are many reports 
confirming the significant role of early detection of viraemia before the appearance of 
clinical symptoms (Legrand et al, 2001; Teramura et al., 2004; Watzinger et al., 2004). 
Initiation of antiviral treatment before the onset of invasive disease is beneficial.  It was 
documented that even intravenous supplementation of antiviral agent during active virus 
replication does not result in recovery in some patients (Chakrabarti et al, 1999). Therefore, 
an early diagnosis of infection and adequately early implementation of antiviral therapy can 
significantly reduce the effects of AdV infections (Chakrabarti et al., 2002; Gavin & Katz, 
2002; Sivaprakasam et al., 2007; Walls et al., 2003). Drug cytotoxicity and its limited efficacy 
in adenoviral infections should encourage clinicians to focus on an earlier diagnostics and 
monitoring of adenoviral infections.  
In recent years, immunomodulation has been most frequently proposed as a new 
therapeutic strategy. Adoptive transfer of T-cell immunity from the donor to the recipient 
(DLI) and infusion of donor immunoglobulins (IVIG) combined with reduced 
immunosupression has become a new treatment option for patients with an insufficient 
number of AdV-specific T-cells. It was demonstrated that infusion of donor AdV-specific 
lymphocytes T is well tolerated and may lead to partially reconstruction of recipient`s 
immune system leading to prophylactics or treatment of adenoviral infections (Amrolia et 
al., 2006; Bordigoni et al., 2001; Feuchtinger et al., 2008; Fujita et al., 2008; Ison, 2006; Lion et 
al., 2010). Successful reduction of AdV replication is achieved mainly due to infusion of 
selected AdV-specific lymphocytes. Infusion of unselected donor lymphocytes is associated 
with higher risk of aGvHD due to high alloreactivity which requires more aggressive 
immunosupresive therapy conducing development of viral infections (Walter et al., 1995). 
The sufficient immune response is achieved mainly due to infusion of combined 
CD4+/CD8+ (60%) or solely CD4+ (40%) cells (Feuchtinger et al., 2008). However, 
heterogeneity of Adenoviridae family in the context of immunomodulation is questionable. 
Human immune system recognizes the surface determinants of AdV capsid which are 
highly variable between AdV serotypes. Hence, the success of T-cells administration may be 
dependent on infecting serotype (Ebner et al., 2006). On the other hand, human 
adenoviruses exhibit high cross-reactivity against different clinically relevant species of AdV 
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and therefore there is a large chance that successful DLI may become a new therapeutic 
strategy for treatment of adenoviral infections after SCT, as antiviral therapy has revealed 
limited success (Bordigoni et al, 2001; Feuchtinger et al., 2008; Lion et al., 2010). Lion et al. 
(2010) suggested that initiation of cidofovir/adoptive transfer of AdV-specific T cells may 
reduce proliferation of adenovirus until recovery of host immune system. These 
considerations suggest that simultaneous detection and treatment of adenoviral infection at 
early stage might prevent life-treatening disseminated infections in recipients of 
hematopoietic stem cell.  
Anti-adenovirus treatment needs careful consideration in many clinical aspects. The 
knowledge on AdV pathogeneicity needs more elucidation. The retrospective studies of 
Wall et al. (2005), Hale et al. (2003)  and others proved that there is a possibility for 
elimination of high viraemia without any treatment due to sufficient host T-cell response 
(Ephros et al., 2009). The opportunity for ‘watch and wait’ strategy is a new unexplored 
clinical option, but the identification of patients with benign clinical course is impossible yet.  
10. Conclusion 
Taking into account that more than 50000 of hematopoietic stem cell transplantations are 
performed every year and nearly 10000 originate from unrelated donors, the number of 
patients who may be affected from adenoviral infections seems to be significant. In view of 
worldwide distribution of adenoviruses, numerous routes of infection and limited 
effectiveness of anti-AdV treatment, adenoviral infections in patients undergoing 
hematopoietic stem cell transplantations should be always considered as serious, life-
threatening post-transplant complication which demands rapid and unequivocal diagnosis 
defining patient`s outcome. 
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